GlassScriptPhysician profile
Steven D Larsen
NPI 1235579731
$14,216.12
in general payments reported to CMS, 2019-2025
34 companies · $3,021 in 2025
The $3,021 reported for 2025 was more than what 85% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $510 · 2020: $1,049 · 2021: $1,632 · 2022: $1,541 · 2023: $3,523 · 2024: $2,941 · 2025: $3,021.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,911 · Travel and Lodging: $3,574.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,910.69 |
| Travel and Lodging | $3,574.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,662.98 | 2019-2025 | Artisan, Coveredge 32, General - Pain Management |
| Medtronic, INC. | $3,068.84 | 2023-2025 | Synchromedii, Kyphon Express II Kyphopak Tray, Intellis Adaptivestim |
| Nalu Medical, INC. | $2,492.98 | 2021-2024 | Nalu Neurostimulation System |
| Nevro Corp. | $1,426.09 | 2019-2023 | Senza |
| Abbvie INC. | $511.49 | 2022-2025 | |
| Spr Therapeutics, INC | $381.59 | 2022-2025 | Sprint Pns System |
| Relievant Medsystems, INC. | $322.88 | 2021-2023 | Intracept |
| Abbott Laboratories | $275.49 | 2020-2025 | Proclaim, Eterna, Axium |
| Stimwave Technologies Incorporated | $189.15 | 2020 | |
| Glaxosmithkline, LLC. | $154.00 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $143.64 | 2021-2024 | Relistor |
| Avanos Medical | $142.69 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $140.82 | 2021-2022 | |
| Spinal Simplicity, LLC | $135.58 | 2021-2025 | Ha Minuteman G3-R |
| Lundbeck LLC | $130.73 | 2021-2024 | Vyepti |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $122.63 | 2020-2022 | |
| Pfizer INC. | $113.28 | 2019-2023 | |
| Vertos Medical, INC. | $95.69 | 2023-2024 | Mild Device Kit |
| Grt US Holding, INC. | $93.22 | 2021-2022 | |
| Puma Biotechnology, INC. | $90.41 | 2019-2024 | |
| Redhill Biopharma INC. | $80.41 | 2021-2023 | Movantik |
| Averitas Pharma INC. | $79.42 | 2023-2024 | Qutenza |
| Allergan, INC. | $76.22 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $43.12 | 2021 | |
| Collegium Pharmaceutical, INC. | $42.56 | 2023-2024 | Xtampza |
| Lilly USA, LLC | $39.36 | 2020-2021 | |
| Amgen INC. | $33.57 | 2021 | |
| Siemens Medical Solutions USA, INC. | $28.72 | 2023 | Magnetom Free.Max |
| Depuy Synthes Sales INC. | $19.01 | 2025 | Monovisc |
| Biodelivery Sciences International, INC. | $18.80 | 2020 | |
| Radius Health, INC. | $17.84 | 2021 | |
| Seqirus USA INC | $16.90 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.25 | 2022 | |
| Bioventus LLC | $11.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Larsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.